MedPath

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

Phase 3
Completed
Conditions
Lung Cancer
Interventions
Biological: Nivolumab
Other: Placebo
Biological: Ipilimumab
Registration Number
NCT02538666
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

In this study, all patients must have already completed first-line chemotherapy to treat extensive-stage disease small cell lung cancer. The purpose of this study is to show that nivolumab, or nivolumab plus ipilimumab followed by nivolumab by itself, will prolong overall survival when administered as consolidation treatment in patients that are stable or responding after chemotherapy. Patients receiving treatment will be compared with patients taking placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
907
Inclusion Criteria
  • Subjects with histologically or cytologically confirmed extensive stage disease SCLC
  • Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Read More
Exclusion Criteria
  • Subjects with symptomatic Central Nervous System (CNS) metastases
  • Subjects receiving consolidative chest radiation
  • Subjects with active, known, or suspected autoimmune disease are excluded
  • All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline

Other protocol-defined inclusion/exclusion criteria apply

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nivolumab monotherapyNivolumabNivolumab intravenous fusion
Nivolumab and ipilimumab combination therapyIpilimumabNivolumab and ipilimumab intravenous fusion
PlaceboPlaceboPlacebo
Nivolumab and ipilimumab combination therapyNivolumabNivolumab and ipilimumab intravenous fusion
Primary Outcome Measures
NameTimeMethod
Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global PopulationFrom randomization to 400 deaths across the two treatment groups (Nivo+Ipi vs Placebo) (up to approximately 37 months)

OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug

Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS) of Nivolumab Versus PlaceboFrom randomization to the date of death or last known alive date (up to approximately 73 months)

Overall Survival (OS) comparing nivolumab monotherapy versus placebo. OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug.

Overall Survival (OS) of Nivolumab + Ipilimumab Versus NivolumabFrom randomization to the date of death or last known alive date (up to approximately 73 months)

Overall Survival (OS) comparing Nivolumab + Ipilimumab Versus Nivolumab. OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug.

Progression Free Survival (PFS) Per BICRFrom randomization to the date of the first documented tumor progression or death due to any cause (up to approximately 73 months)

PFS was defined as the time between the date of randomization and the first date of documented progression as determined by Blind Independent Central Review (BICR) or death due to any cause, whichever occurred first. Participants who died with no reported progression were considered to have progressed on the date of death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on study tumor assessments and did not die (or died after initiation of the subsequent anti- cancer therapy) were censored on their date of randomization. Participants who started any subsequent anti- cancer therapy without a prior reported Progressive Disease (PD) per BICR were censored at the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.

Overall Survival (OS) in Tumor Mutational Burden (TMB) High and Low Subgroups by TMB Cutoff In The Global PopulationFrom randomization to the date of death or last known alive date (up to approximately 73 months)

Tumor mutational burden (TMB) is measured using FoundationOne CDxTM (F1CDx) assay, a comprehensive genomic profile (CGP) assay based on baseline tumor tissue. TMB is defined as the number of somatic, coding, base substitution, and indel mutations per megabase of genome examined.

OS in TMB by the following cutoff points: ≥10 mutations/mb, \< 10 mutations/mb, ≥13 mutations/mb, \<13 mutations/mb

Progression Free Survival (PFS) Per BICR in Tumor Mutational Burden (TMB) High and Low Subgroups by TMB Cutoff In The Global PopulationFrom randomization to the date of the first documented tumor progression or death due to any cause (up to approximately 73 months)

Tumor mutational burden (TMB) is measured using FoundationOne CDxTM (F1CDx) assay, a comprehensive genomic profile (CGP) assay based on baseline tumor tissue. TMB is defined as the number of somatic, coding, base substitution, and indel mutations per megabase of genome examined.

PFS in TMB by the following cutoff points: ≥10 mutations/mb, \< 10 mutations/mb, ≥13 mutations/mb, \<13 mutations/mb.

Trial Locations

Locations (176)

Local Institution - 0020

🇲🇽

Leon de los Aldama, Guanajuato, Mexico

Local Institution - 0063

🇧🇷

Ijui, RIO Grande DO SUL, Brazil

Local Institution - 0244

🇨🇳

Wuhang, Hubei, China

Local Institution - 0230

🇨🇳

Nanchang, Jiangxi, China

Local Institution - 0237

🇨🇳

Shenyang, Liaoning, China

Local Institution - 0228

🇨🇳

Shanghai, Shanghai, China

Local Institution - 0239

🇨🇳

Hangzhou, Zhejiang, China

Local Institution - 0014

🇺🇸

Durham, North Carolina, United States

Local Institution - 0129

🇺🇸

Cincinnati, Ohio, United States

Local Institution - 0001

🇺🇸

Portland, Oregon, United States

Local Institution - 0034

🇺🇸

Portland, Oregon, United States

Local Institution - 0142

🇯🇵

Matsuyama-shi, Ehime, Japan

Local Institution - 0143

🇯🇵

Sapporo-shi, Hokkaido, Japan

Local Institution - 0083

🇯🇵

Takatsuki-shi, Osaka, Japan

Local Institution - 0127

🇺🇸

Fort Myers, Florida, United States

Local Institution - 0004

🇺🇸

Allentown, Pennsylvania, United States

Local Institution - 0013

🇺🇸

Indianapolis, Indiana, United States

Local Institution - 0008

🇺🇸

New York, New York, United States

Local Institution - 0003

🇺🇸

Sacramento, California, United States

Local Institution - 0015

🇺🇸

Saint Louis, Missouri, United States

Local Institution - 0107

🇺🇸

Boston, Massachusetts, United States

Local Institution - 0032

🇺🇸

Lexington, Kentucky, United States

Local Institution - 0213

🇺🇸

Sioux Falls, South Dakota, United States

Local Institution - 0035

🇦🇺

East Melbourne, Victoria, Australia

Local Institution

🇪🇸

Sevilla, Spain

Local Institution - 0188

🇦🇷

Cordoba, Argentina

Local Institution - 0173

🇦🇹

Salzburg, Austria

Local Institution - 0137

🇦🇺

Adelaide, South Australia, Australia

Local Institution - 0233

🇨🇳

Shanghai, Shanghai, China

Local Institution - 0245

🇨🇳

Shanghai, Shanghai, China

Local Institution - 0080

🇬🇷

N.Kifissia, Greece

Local Institution - 0240

🇨🇳

Guangzhou, China

Local Institution - 0128

🇺🇸

Saint Petersburg, Florida, United States

Local Institution - 0094

🇨🇦

Edmonton, Alberta, Canada

Local Institution - 0002

🇺🇸

Sayre, Pennsylvania, United States

Local Institution - 0238

🇨🇳

Hefei, Anhui, China

Local Institution - 0243

🇨🇳

Hefei, Anhui, China

Local Institution - 0221

🇨🇳

Harbin, Heilongjiang, China

Local Institution - 0248

🇨🇳

Nantong, Jiangsu, China

Local Institution - 0111

🇨🇦

Windsor, Ontario, Canada

Local Institution - 0029

🇦🇷

Tucuman, Argentina

Local Institution - 0123

🇨🇦

Oshawa, Ontario, Canada

Local Institution - 0232

🇨🇳

Kunming, Yunnan, China

Local Institution - 0068

🇧🇷

Belo Horizonte, Minas Gerais, Brazil

Local Institution - 0166

🇩🇪

Gauting, Germany

Local Institution - 0102

🇨🇦

Sudbury, Ontario, Canada

Local Institution - 0220

🇨🇳

Shanghai, Shanghai, China

Princess Alexandra Hospital

🇦🇺

Brisbane, Queensland, Australia

Local Institution - 0081

🇧🇷

Barretos, Sao Paulo, Brazil

Local Institution - 0097

🇫🇷

Paris Cedex 20, France

Local Institution - 0247

🇨🇳

Changsha, China

Local Institution - 0150

🇫🇷

Saint Herblain, France

Local Institution - 0096

🇫🇷

Toulouse, France

Local Institution - 0078

🇨🇴

Bogota, Colombia

Local Institution - 0045

🇫🇮

Turku, Finland

Local Institution - 0046

🇫🇮

Vaasa, Finland

Local Institution - 0208

🇫🇷

Avignon Cedes 9, France

Local Institution - 0098

🇫🇷

Marseille Cedex 20, France

Local Institution - 0246

🇨🇳

Wenzhou, Zhejiang, China

Local Institution - 0112

🇮🇹

Messina, Italy

Local Institution - 0171

🇩🇪

Augsburg, Germany

Local Institution - 0099

🇫🇷

Lyon Cedex 08, France

Local Institution - 0139

🇯🇵

Kashiwa-shi, Chiba, Japan

Local Institution - 0072

🇯🇵

Yokohama-shi, Kanagawa, Japan

Local Institution - 0090

🇮🇱

Tel Aviv, Israel

Local Institution - 0100

🇫🇷

Rennes Cedex 9, France

Local Institution - 0095

🇫🇷

Pierre Benite, France

Interbalkan European Medical Center

🇬🇷

Thessaloniki, Greece

Local Institution - 0164

🇩🇪

Bochum, Germany

Local Institution - 0025

🇮🇹

Bologna, Italy

Local Institution - 0146

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Local Institution - 0027

🇮🇹

Milan, Lombardia, Italy

Local Institution - 0026

🇮🇹

Avellino, Italy

Local Institution - 0076

🇯🇵

Kobe-shi, Hyogo, Japan

Local Institution - 0145

🇯🇵

Osaka-shi, Osaka, Japan

Local Institution - 0082

🇮🇹

Perugia, Italy

Local Institution - 0200

🇯🇵

Kurume-shi, Fukuoka, Japan

Local Institution - 0198

🇯🇵

Gifu-shi, Gifu, Japan

Local Institution - 0069

🇯🇵

Sendai-shi, Miyagi, Japan

Local Institution - 0138

🇯🇵

Kanazawa-shi, Ishikawa, Japan

Local Institution - 0077

🇯🇵

Kurashiki-shi, Okayama, Japan

Local Institution - 0159

🇳🇱

Rotterdam, Netherlands

Local Institution - 0070

🇯🇵

Sendai-shi, Miyagi, Japan

Local Institution - 0135

🇲🇽

Queretaro, Mexico

Local Institution - 0157

🇷🇺

St Petersburg, Russian Federation

Local Institution - 0115

🇷🇺

St Petersburg, Russian Federation

Local Institution - 0087

🇿🇦

Sandton, Gauteng, South Africa

Local Institution - 0067

🇧🇷

Fortaleza, Ceara, Brazil

Local Institution - 0168

🇩🇪

Berlin, Germany

Local Institution - 0169

🇩🇪

Immenhausen, Germany

Local Institution - 0093

🇮🇱

Jerusalem, Israel

Local Institution - 0207

🇺🇸

Boston, Massachusetts, United States

Local Institution - 0005

🇺🇸

Charleston, South Carolina, United States

Local Institution - 0009

🇺🇸

Columbus, Ohio, United States

Local Institution - 0006

🇺🇸

Richmond, Virginia, United States

Local Institution - 0010

🇺🇸

Atlanta, Georgia, United States

Local Institution - 0061

🇺🇸

Fairway, Kansas, United States

Local Institution - 0051

🇺🇸

Baltimore, Maryland, United States

Local Institution - 0007

🇺🇸

Jacksonville, Florida, United States

Local Institution - 0215

🇺🇸

Fargo, North Dakota, United States

Local Institution - 0011

🇺🇸

Salt Lake City, Utah, United States

Local Institution - 0110

🇦🇷

Berazategui, Buenos Aires, Argentina

Local Institution - 0017

🇧🇷

Itajai, Santa Catarina, Brazil

Local Institution - 0167

🇩🇪

Tübingen, Germany

Local Institution - 0149

🇫🇷

Strasbourg, Alsace, France

Local Institution - 0227

🇨🇳

Hangzhou, Zhejiang, China

Local Institution - 0170

🇩🇪

Bad Berka, Germany

Local Institution - 0165

🇩🇪

Grosshansdorf, Germany

Local Institution - 0089

🇮🇱

Zerifin, Israel

Local Institution - 0075

🇯🇵

Osaka-sayama-shi, Osaka, Japan

Local Institution - 0193

🇯🇵

Hidaka, Saitama, Japan

Local Institution - 0140

🇯🇵

Koto-ku, Tokyo, Japan

Local Institution - 0071

🇯🇵

Chuo-ku, Tokyo, Japan

Local Institution - 0144

🇯🇵

Shinjuku-ku, Tokyo, Japan

Local Institution - 0216

🇯🇵

Wakayama, Japan

Local Institution - 0047

🇰🇷

Seongnam-si, Gyeonggi-do, Korea, Republic of

Local Institution - 0022

🇰🇷

Seoul, Korea, Republic of

Local Institution - 0154

🇰🇷

Seoul, Korea, Republic of

Local Institution - 0024

🇰🇷

Suwon, Kyǒnggi-do, Korea, Republic of

Local Institution - 0021

🇰🇷

Gangnam-gu, Korea, Republic of

Local Institution - 0028

🇲🇽

Monterrey, Nuevo Leon, Mexico

Local Institution - 0019

🇲🇽

Mexico, Distrito Federal, Mexico

Local Institution - 0158

🇳🇱

's-Hertogenbosch, Netherlands

Local Institution - 0054

🇵🇱

Gdynia, Poland

Local Institution - 0041

🇵🇱

Gdansk, Poland

Local Institution - 0186

🇷🇴

Bucharest, Romania

Local Institution - 0053

🇵🇱

Olsztyn, Poland

Local Institution - 0187

🇵🇱

Warszawa, Poland

Local Institution - 0209

🇷🇺

Moscow, Russian Federation

Local Institution - 0182

🇷🇴

Craiova, Romania

Local Institution - 0178

🇷🇴

Lasi, Romania

Local Institution - 0212

🇷🇴

Romania, Romania

Local Institution - 0148

🇷🇺

Moscow, Russian Federation

Local Institution - 0181

🇷🇴

Timisoara, Timis, Romania

Local Institution - 0217

🇷🇺

Moscow, Russian Federation

Local Institution - 0116

🇷🇺

St. Petersburg, Russian Federation

Local Institution - 0086

🇿🇦

George, Western CAPE, South Africa

Local Institution - 0084

🇿🇦

Cape Town, Western Cape, South Africa

Local Institution - 0085

🇿🇦

Cape Town, Western CAPE, South Africa

Local Institution - 0050

🇸🇬

Singapore, Singapore

Local Institution - 0124

🇸🇪

Lund, Sweden

Local Institution - 0185

🇸🇪

Uppsala, Sweden

Local Institution - 0132

🇪🇸

Barcelona, Spain

Local Institution - 0179

🇨🇭

Aarau, Switzerland

Local Institution - 0191

🇨🇭

St. Gallen, Switzerland

Local Institution - 0153

🇬🇧

Truro, Cornwall, United Kingdom

Local Institution - 0049

🇨🇳

Tainan, TNN, Taiwan

Local Institution - 0201

🇬🇧

London, Greater London, United Kingdom

Local Institution - 0118

🇬🇧

London, Greater London, United Kingdom

Local Institution - 0048

🇨🇳

Taoyuan, Taiwan

Local Institution - 0152

🇬🇧

Oxford, Oxfordshire, United Kingdom

Local Institution - 0151

🇬🇧

Sutton, Surrey, United Kingdom

Local Institution - 0192

🇬🇧

Sheffield, United Kingdom

Local Institution - 0121

🇬🇧

Wirral, Lancashire, United Kingdom

Local Institution - 0109

🇦🇷

Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina

Local Institution - 0059

🇧🇪

Charleroi, Belgium

Local Institution - 0175

🇮🇪

Dublin, Ireland

Local Institution - 0214

🇮🇪

Limerick, Ireland

Local Institution - 0199

🇷🇴

Bucharest, Romania

Local Institution - 0136

🇨🇦

Moncton, New Brunswick, Canada

Local Institution - 0172

🇦🇹

Wien, Austria

Local Institution - 0060

🇧🇪

Roeselare, Belgium

Local Institution - 0043

🇫🇮

Tampere, Finland

Local Institution - 0141

🇯🇵

Bunkyo-ku, Tokyo, Japan

Local Institution - 0057

🇧🇪

Brussels, Belgium

Local Institution - 0180

🇨🇭

Geneve, Switzerland

Local Institution - 0044

🇫🇮

Oulu, Finland

Local Institution - 0174

🇦🇹

Innsbruck, Austria

Local Institution - 0161

🇮🇪

Wilton, Cork, Ireland

Local Institution - 0162

🇮🇪

Galway, Ireland

Local Institution - 0202

🇺🇸

New Haven, Connecticut, United States

Local Institution - 0012

🇺🇸

Wichita, Kansas, United States

Local Institution - 0016

🇺🇸

Winston-Salem, North Carolina, United States

Local Institution - 0064

🇧🇷

Porto Alegre, RIO Grande DO SUL, Brazil

Local Institution - 0088

🇦🇷

Capital Federal, Buenos Aires, Argentina

Local Institution - 0052

🇭🇰

Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath